Viatris Inc (VTRS)
13.37
+0.12
(+0.91%)
USD |
NASDAQ |
Nov 22, 16:00
13.38
0.00 (0.00%)
After-Hours: 20:00
Viatris Revenue (Annual): 15.43B for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 15.43B |
December 31, 2022 | 16.26B |
December 31, 2021 | 17.89B |
December 31, 2020 | 11.95B |
December 31, 2019 | 11.50B |
December 31, 2018 | 11.43B |
December 31, 2017 | 11.91B |
December 31, 2016 | 11.08B |
December 31, 2015 | 9.429B |
December 31, 2014 | 7.720B |
December 31, 2013 | 6.909B |
December 31, 2012 | 6.796B |
December 31, 2011 | 6.130B |
December 31, 2010 | 5.451B |
December 31, 2009 | 5.093B |
December 31, 2008 | 5.138B |
December 31, 2007 | 2.179B |
March 31, 2007 | 1.612B |
March 31, 2006 | 1.257B |
March 31, 2005 | 1.253B |
March 31, 2004 | 1.375B |
Date | Value |
---|---|
March 31, 2003 | 1.269B |
March 31, 2002 | 1.104B |
March 31, 2001 | 846.70M |
March 31, 2000 | 790.14M |
March 31, 1999 | 721.10M |
March 31, 1998 | 528.60M |
March 31, 1997 | 440.20M |
March 31, 1996 | 392.90M |
March 31, 1995 | 396.10M |
March 31, 1994 | 251.80M |
March 31, 1993 | 212.00M |
March 31, 1992 | 131.90M |
March 31, 1991 | 91.10M |
March 31, 1990 | 95.40M |
March 31, 1989 | 87.90M |
March 31, 1988 | 96.00M |
March 31, 1987 | 95.10M |
March 31, 1986 | 80.80M |
March 31, 1985 | 53.60M |
March 31, 1984 | 36.90M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
11.50B
Minimum
2019
17.89B
Maximum
2021
14.60B
Average
15.43B
Median
2023
Revenue (Annual) Benchmarks
Lexicon Pharmaceuticals Inc | 1.204M |
Moderna Inc | 6.754B |
Baxter International Inc | 14.81B |
Gilead Sciences Inc | 27.12B |
Perspective Therapeutics Inc | -- |